Week 12 EVR predicts EOT in CHC genotype 4 patients treated with peginterferon alfa-2a (40KD)/RBV

Autor:	Ossama A. Shobokshi, H. Eissa, K. Qahtani, M. El-Hazmi, A. Al-Blowi, A. Sandokji, M. Al-Khalifa, A. Ayoola, Frank E. Serebour, F. Khawajah, H. Akbar, A. Humaida, Leila Skakni, M. Al-Karawi, T. Dinish, Bashar M. Al-Kayyal, A. Sabah, M. Al-Quaiz, S. Al-Momen, N. Al-Jasser, A.O. Tantawi, I. El-Hazmi
Rok vydání:	2003
Předmět:	medicine.medical_specialty Hepatology business.industry Internal medicine Genotype medicine business Gastroenterology Peginterferon alfa-2a medicine.drug
Zdroj:	Journal of Hepatology. 38:172
ISSN:	0168-8278
DOI:	10.1016/s0168-8278(03)80859-0
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::4287e2357b347d9f73a2e70cc314fc74 https://doi.org/10.1016/s0168-8278(03)80859-0 Zobrazit plný text záznamu Full Text from ScienceDirect